Sanofi links up with Hanmi for portfolio of long-acting diabetes treatments

5 November 2015

French pharma major Sanofi (Euronext: SAN) has entered into a worldwide license agreement with South Korea’s Hanmi Pharmaceutical to develop a portfolio of experimental, long-acting diabetes treatments.

Under the terms of the accord, Hanmi will receive an upfront payment of 400 million euros ($434.4 million) and is eligible for up to 3.5 billion euros in development, registration and sales milestones, as well as double-digit royalties on net sales. The agreement is subject to customary closing conditions including review under the Hart-Scott-Rodino Antitrust Improvements Act.

Deal includes late-stage agent efpeglenatide

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical